Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Icatibant relieves acute attacks in hereditary angioedema

11 Dec 2019

The selective bradykinin B2 receptor antagonist icatibant proves to be effective and safe for managing acute attacks in Japanese patients with hereditary angioedema (HAE), according to the results of a small phase III open-label trial.

In the trial, eight HAE patients who had an attack affecting the skin (n=4), abdomen (n=3) or larynx (n=1) received icatibant 30 mg via subcutaneous injection in the abdomen administered by the patient or a healthcare professional.

Symptom relief occurred after a median of 1.75 hours (95 percent confidence interval [CI], 1.00–2.50) of treatment, with all patients achieving symptom relief within 5 hours after administration.

The time to maximum plasma concentration of icatibant was 1.79 hours, with the maximum plasma concentration being 405 ng/ml.

In terms of safety, injection site reaction occurred in seven patients. There were three adverse events recorded: worsening of HAE 29 hours after treatment, repeat HAE attack 18.3 hours after treatment and a headache.

Regardless of the small number of patients included in the study, the findings confirm that subcutaneous icatibant administration may quickly relieve the symptoms of acute HAE attacks, according to researchers.

An autosomal-dominant genetic disease characterized by recurrent swelling episodes, HAE attacks are unpredictable in terms of onset, duration, severity, frequency and anatomical location. Furthermore, attacks affecting the larynx may be life-threatening. [Am J Gastroenterol 2006;101:619-627; J Allergy Clin Immunol 2012;130:692-697]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.